Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Operating Leases (2019 - 2024)

Historic Operating Leases for Arcadia Biosciences (RKDA) over the last 6 years, with Q2 2024 value amounting to $11000.0.

  • Arcadia Biosciences' Operating Leases fell 9793.23% to $11000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $11000.0, marking a year-over-year decrease of 9793.23%. This contributed to the annual value of $155000.0 for FY2023, which is 8460.77% down from last year.
  • Arcadia Biosciences' Operating Leases amounted to $11000.0 in Q2 2024, which was down 9793.23% from $21000.0 recorded in Q1 2024.
  • Over the past 5 years, Arcadia Biosciences' Operating Leases peaked at $5.7 million during Q2 2021, and registered a low of $11000.0 during Q2 2024.
  • Over the past 5 years, Arcadia Biosciences' median Operating Leases value was $1.6 million (recorded in 2022), while the average stood at $2.5 million.
  • In the last 5 years, Arcadia Biosciences' Operating Leases surged by 28441.38% in 2020 and then tumbled by 9793.23% in 2024.
  • Arcadia Biosciences' Operating Leases (Quarter) stood at $5.4 million in 2020, then plummeted by 58.8% to $2.2 million in 2021, then plummeted by 54.64% to $1.0 million in 2022, then plummeted by 84.61% to $155000.0 in 2023, then tumbled by 92.9% to $11000.0 in 2024.
  • Its Operating Leases was $11000.0 in Q2 2024, compared to $21000.0 in Q1 2024 and $155000.0 in Q4 2023.